Physician profile
Ashley Sprinkle
NPI 1629855580
$2,687.04
in general payments reported to CMS, 2019-2025
23 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $289 · 2024: $991 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,687.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $518.42 | 2024-2025 | Fanapt |
| Abbvie INC. | $496.37 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $337.18 | 2023-2025 | Rexulti |
| Gilead Sciences, INC. | $324.15 | 2023-2024 | Veklury |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $230.94 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $117.67 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Azurity Pharmaceuticals, INC. | $104.66 | 2024-2025 | Horizant |
| Novo Nordisk INC | $100.18 | 2023-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $73.47 | 2024-2025 | Breztri, Airsupra |
| Sanofi-Aventis U.S. LLC | $55.78 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $50.47 | 2025 | Cobenfy, Eliquis |
| Glaxosmithkline, LLC. | $49.81 | 2023-2025 | Trelegy Ellipta |
| Amgen INC. | $32.95 | 2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $26.58 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $26.00 | 2025 | Uzedy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.32 | 2024 | Freestyle Libre 3 |
| Aimmune Therapeutics, INC. | $23.82 | 2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $17.01 | 2024 | Trintellix |
| Lilly USA, LLC | $16.52 | 2024 | Mounjaro, Zepbound |
| Lundbeck LLC | $15.57 | 2024 | Rexulti |
| Smith+Nephew, INC. | $15.27 | 2025 | Collagenase Santyl |
| Pfizer INC. | $15.12 | 2024 | |
| Alkermes, INC. | $14.78 | 2024 | Vivitrol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Sprinkle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.